---
title: "EuroPCR 2024: TAVI device with intermediate sizing shown to be non-inferior to contemporary platforms in LANDMARK trial"
date: "2024-05-16T06:41:20.000Z"
publishedDate: "16 mai 2024"
summary: "Early outcomes following the use of a novel balloon-expandable transcatheter aortic valve implantation (TAVI) device, compared in a randomised trial against two commercially available TAVI valves, have been shared for the first time at EuroPCR 2024 (13–17 May, Paris, France). Results of the LANDMARK multicentre trial comparing the use of the MyVal (Meril) TAVI valve [&#8230;] The post EuroPCR 2024: TAVI device with intermediate sizing shown to be non-inferior to contemporary platforms in LANDMARK trial appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/europcr-2024-landmark-trial/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-05-16-europcr-2024-tavi-device-with-intermediate-sizing-shown-to-be-non-inferior-to-contemporary-platforms-in-landmark-trial"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/05/Patrick-Serruys.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/europcr-2024-landmark-trial/"
---

![EuroPCR 2024: TAVI device with intermediate sizing shown to be non-inferior to contemporary platforms in LANDMARK trial](https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/05/Patrick-Serruys.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/europcr-2024-landmark-trial/*

## L’essentiel

Early outcomes following the use of a novel balloon-expandable transcatheter aortic valve implantation (TAVI) device, compared in a randomised trial against two commercially available TAVI valves, have been shared for the first time at EuroPCR 2024 (13–17 May, Paris, France). Results of the LANDMARK multicentre trial comparing the use of the MyVal (Meril) TAVI valve [&#8230;] The post EuroPCR 2024: TAVI device with intermediate sizing shown to be non-inferior to contemporary platforms in LANDMARK trial appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/europcr-2024-landmark-trial/
